DOCSLIB.ORG

KDM5D (NM 001146705) Human Tagged ORF Clone Product Data

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
KDM5D (NM 001146705) Human Tagged ORF Clone Product Data OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for RC229081 KDM5D (NM_001146705) Human Tagged ORF Clone Product data: Product Type: Expression Plasmids Product Name: KDM5D (NM_001146705) Human Tagged ORF Clone Tag: Myc-DDK Symbol: KDM5D Synonyms: HY; HYA; JARID1D; SMCY Vector: pCMV6-Entry (PS100001) E. coli Selection: Kanamycin (25 ug/mL) Cell Selection: Neomycin ORF Nucleotide >RC229081 representing NM_001146705 Sequence: Red=Cloning site Blue=ORF Green=Tags(s) TTTTGTAATACGACTCACTATAGGGCGGCCGGGAATTCGTCGACTGGATCCGGTACCGAGGAGATCTGCC GCCGCGATCGCC ATGGAACCGGGGTGTGACGAGTTCCTGCCGCCACCGGAGTGCCCGGTTTTTGAGCCTAGCTGGGCTGAAT TCCAAGACCCGCTTGGCTACATTGCGAAAATAAGGCCCATAGCAGAGAAGTCTGGCATCTGCAAAATCCG CCCACCCGCGGATTGGCAGCCTCCTTTTGCAGTAGAAGTTGACAATTTCAGATTTACTCCTCGCGTCCAA AGGCTAAATGAACTGGAGGCCCAAACTAGAGTGAAATTGAACTATTTGGATCAGATTGCAAAATTCTGGG AAATTCAAGGCTCCTCTTTAAAGATTCCCAATGTGGAGCGGAAGATCTTGGACCTCTACAGCCTTAGTAA GATTGTGATTGAGGAAGGTGGCTATGAAGCCATCTGCAAGGATCGTCGGTGGGCTCGAGTTGCCCAGCGT CTCCACTACCCACCAGGCAAAAACATTGGCTCCCTGCTACGATCACATTACGAACGCATTATTTACCCCT ATGAAATGTTTCAGTCTGGAGCCAACCATGTGCAATGTAACACACACCCGTTTGACAATGAGGTAAAAGA TAAGGAATACAAGCCCCACAGCATCCCCCTTAGACAGTCTGTGCAGCCTTCAAAGTTCAGCAGCTACAGT CGACGGGCAAAAAGGCTACAGCCTGATCCAGAGCCTACAGAGGAGGACATTGAGAAGCATCCAGAGCTAA AGAAGTTACAGATATATGGGCCAGGTCCCAAAATGATGGGCTTGGGCCTTATGGCTAAGGATAAGGATAA GACTGTGCATAAGAAAGTCACATGCCCCCCAACTGTTACGGTGAAGGATGAGCAAAGTGGAGGTGGGAAC GTGTCATCAACATTGCTCAAGCAGCACTTGAGCCTAGAGCCCTGCACTAAGACAACCATGCAACTTCGAA AGAATCACAGCAGTGCCCAGTTTATTGACTCATATATTTGCCAAGTATGCTCCCGTGGGGATGAAGATGA TAAGCTTCTTTTCTGTGATGGCTGTGATGACAATTACCACATCTTCTGCTTGTTACCACCCCTTCCTGAA ATCCCCAGAGGCATCTGGAGGTGCCCAAAATGTATCTTGGCGGAGTGTAAACAGCCTCCTGAAGCTTTTG GATTTGAACAGGCTACCCAGGAGTACAGTTTGCAGAGTTTTGGTGAAATGGCTGATTCCTTCAAGTCCGA CTACTTCAACATGCCTGTACATATGGTGCCTACAGAACTTGTAGAGAAGGAATTCTGGAGGCTGGTGAGC AGCATTGAGGAAGACGTGACAGTTGAATATGGAGCTGATATTCATTCCAAAGAATTTGGCAGTGGCTTTC CTGTCAGCAATAGCAAACAAAACTTATCTCCTGAGGAGAAGAGACAAAGTCTCACTGTGTTGACCAGGCT GATCTCAAGCTTCTGGGCTCAAGCAGTCCTCCCACCTTGGCCTCCCAAAGTGTTGGGATTACAGGAGTAT GCGACCAGTGGTTGGAACCTGAATGTGATGCCAGTGCTAGATCAGTCTGTTCTCTGTCACATCAATGCAG This product is to be used for laboratory only. Not for diagnostic or therapeutic use. View online » ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 1 / 5 KDM5D (NM_001146705) Human Tagged ORF Clone – RC229081 ACATCTCAGGCATGAAGGTGCCCTGGCTGTACGTGGGCATGGTTTTCTCAGCATTTTGTTGGCATATTGA GGATCACTGGAGTTACTCTATTAACTATCTGCATTGGGGTGAGCCGAAGACCTGGTATGGTGTACCCTCC CTGGCAGCAGAGCATTTGGAGGAGGTGATGAAGATGCTGACACCTGAGCTGTTTGATAGCCAGCCTGATC TCCTACACCAGCTTGTCACTCTCATGAATCCCAACACTTTGATGTCCCATGGTGTGCCAGTTGTCCGCAC AAACCAGTGTGCAGGGGAGTTTGTCATCACTTTTCCTCGTGCTTACCACAGTGGTTTTAACCAAGGCTAC AATTTTGCTGAAGCTGTCAACTTTTGTACTGCTGACTGGCTACCTGCTGGACGCCAGTGCATTGAACACT ACCGCCGGCTCCGGCGCTATTGTGTCTTCTCCCACGAGGAGCTCATCTGCAAGATGGCTGCCTTCCCAGA GACGTTGGATCTCAATCTAGCAGTAGCTGTGCACAAGGAGATGTTCATTATGGTTCAGGAGGAGCGACGT CTACGAAAGGCCCTTTTGGAGAAGGGCGTCACGGAGGCTGAGCGAGAGGCTTTTGAGCTGCTCCCAGATG ATGAACGCCAGTGCATCAAGTGCAAGACCACGTGCTTCTTGTCAGCCCTGGCCTGCTACGACTGCCCAGA TGGCCTTGTATGCCTTTCCCACATCAATGACCTCTGCAAGTGCTCTAGTAGCCGACAGTACCTCCGGTAT CGGTACACCTTGGATGAGCTCCCCACCATGCTGCATAAACTGAAGATTCGGGCTGAGTCTTTTGACACCT GGGCCAACAAAGTGCGAGTGGCCTTGGAGGTGGAGGATGGCCGTAAACGCAGCTTTGAAGAGCTAAGGGC ACTGGAGTCTGAGGCTCGTGAGAGGAGGTTTCCTAATAGTGAGCTGCTTCAGCGACTGAAGAACTGCCTG AGTGAGGTGGAGGCTTGTATTGCTCAAGTCCTGGGGCTGGTCAGTGGTCAGGTGGCCAGGATGGACACTC CACAGCTGACCTTGACTGAACTCCGGGTCCTTCTTGAGCAGATGGGCAGCCTGCCCTGTGCCATGCATCA GATTGGGGATGTCAAGGATGTCCTGGAACAGGTGGAGGCCTATCAAGCTGAGGCTCGTGAGGCTCTGGCC ACACTGCCCTCTAGTCCAGGGCTATTGCGGTCCCTGTTGGAGAGGGGGCAGCAGCTGGGTGTAGAGGTGC CTGAAGCCCATCAGCTTCAGCAGCAGGTGGAGCAGGCGCAATGGCTAGATGAAGTGAAGCAGGCCCTGGC CCCTTCTGCTCACAGGGGCTCTCTGGTCATCATGCAGGGGCTTTTGGTTATGGGTGCCAAGATAGCCTCC AGCCCTTCTGTGGACAAGGCCCGGGCTGAGCTGCAAGAACTACTGACCATTGCAGAGCGCTGGGAAGAAA AGGCTCATTTCTGCCTGGAGGCCAGGCAGAAGCATCCACCAGCCACATTGGAAGCCATAATTCGTGAGAC AGAAAACATCCCTGTTCACCTGCCTAACATCCAGGCTCTCAAAGAAGCTCTGACTAAGGCACAAGCTTGG ATTGCTGATGTGGATGAGATCCAAAATGGTGACCACTACCCCTGTCTAGATGACTTGGAGGGCCTGGTGG CTGTGGGCCGGGACCTGCCTGTGGGGCTGGAAGAGCTGAGACAGCTAGAGCTGCAGGTATTGACAGCACA TTCCTGGAGAGAGAAGGCCTCCAAGACCTTTCTCAAGAAGAATTCTTGCTACACACTGCTTGAGGTGCTT TGCCCGTGTGCAGACGCTGGCTCAGACAGCACCAAGCGTAGCCGGTGGATGGAGAAGGCGCTGGGGTTGT ACCAGTGTGACACAGAGCTGCTGGGGCTGTCTGCACAGGACCTCAGAGACCCAGGCTCTGTGATTGTGGC CTTCAAGGAAGGGGAACAGAAGGAGAAGGAGGGTATCCTGCAGCTGCGTCGCACCAACTCAGCCAAGCCC AGTCCACTGGCACCATCCCTCATGGCCTCTTCTCCGACTTCTATCTGTGTGTGTGGGCAGGTGCCAGCTG GGGTGGGAGTTCTGCAGTGTGACCTGTGTCAGGACTGGTTCCATGGGCAGTGTGTGTCAGTGCCCCATCT CCTCACCTCTCCAAAGCCCAGTCTCACTTCATCTCCACTGCTAGCCTGGTGGGAATGGGACACAAAATTC CTGTGTCCACTGTGTATGCGCTCACGACGGCCACGCCTAGAGACAATCCTAGCCTTGCTGGTTGCCCTGC AGAGGCTGCCCGTGCGGCTGCCTGAGGGTGAGGCCCTTCAGTGTCTCACAGAGAGGGCCATTGGCTGGCA AGACCGTGCCAGAAAGGCTCTGGCCTCTGAAGATGTGACTGCTCTGTTGCGACAGCTGGCTGAGCTTCGC CAACAGCTACAGGCCAAACCCAGACCAGAGGAGGCCTCAGTCTACACTTCAGCCACTGCCTGTGACCCTA TCAGAGAAGGCAGTGGCAACAATATTTCTAAGGTCCAAGGGCTGCTGGAGAATGGAGACAGTGTGACCAG TCCTGAGAACATGGCTCCAGGAAAGGGCTCTGACCTGGAGCTACTGTCCTCACTGTTGCCGCAGTTGACT GGCCCTGTGTTGGAGCTGCCTGAGGCAATCCGGGCTCCCCTGGAGGAGCTCATGATGGAAGGGGACCTGC TTGAGGTGACCCTGGATGAGAACCACAGCATCTGGCAGCTGCTGCAGGCTGGACAGCCTCCAGACCTGGA CAGAATTCGCACACTTCTGGAGCTGGAAAAATTTGAACATCAAGGGAGTCGGACAAGGAGCCGGGCTCTG GAGAGGCGACGGCGGCGGCAGAAGGTGGATCAGGGTAGAAACGTTGAGAATCTTGTTCAACAGGAGCTTC AGTCAAAAAGGGCTCGGAGCTCAGGGATTATGTCTCAGGTGGGCCGAGAAGAAGAACATTATCAGGAGAA AGCAGACCGTGAAAATATGTTCCTGACACCTTCCACAGACCACAGCCCTTTCTTGAAAGGAAACCAAAAT AGCTTACAACACAAGGATTCAGGCTCTTCAGCTGCTTGTCCTTCTTTAATGCCTTTGCTACAACTCTCCT ACTCTGATGAGCAACAGTTG ACGCGTACGCGGCCGCTCGAGCAGAAACTCATCTCAGAAGAGGATCTGGCAGCAAATGATATCCTGGATT ACAAGGATGACGACGATAAGGTTTAA This product is to be used for laboratory only. Not for diagnostic or therapeutic use. ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 2 / 5 KDM5D (NM_001146705) Human Tagged ORF Clone – RC229081 Protein Sequence: >RC229081 representing NM_001146705 Red=Cloning site Green=Tags(s) MEPGCDEFLPPPECPVFEPSWAEFQDPLGYIAKIRPIAEKSGICKIRPPADWQPPFAVEVDNFRFTPRVQ RLNELEAQTRVKLNYLDQIAKFWEIQGSSLKIPNVERKILDLYSLSKIVIEEGGYEAICKDRRWARVAQR LHYPPGKNIGSLLRSHYERIIYPYEMFQSGANHVQCNTHPFDNEVKDKEYKPHSIPLRQSVQPSKFSSYS RRAKRLQPDPEPTEEDIEKHPELKKLQIYGPGPKMMGLGLMAKDKDKTVHKKVTCPPTVTVKDEQSGGGN VSSTLLKQHLSLEPCTKTTMQLRKNHSSAQFIDSYICQVCSRGDEDDKLLFCDGCDDNYHIFCLLPPLPE IPRGIWRCPKCILAECKQPPEAFGFEQATQEYSLQSFGEMADSFKSDYFNMPVHMVPTELVEKEFWRLVS SIEEDVTVEYGADIHSKEFGSGFPVSNSKQNLSPEEKRQSLTVLTRLISSFWAQAVLPPWPPKVLGLQEY ATSGWNLNVMPVLDQSVLCHINADISGMKVPWLYVGMVFSAFCWHIEDHWSYSINYLHWGEPKTWYGVPS LAAEHLEEVMKMLTPELFDSQPDLLHQLVTLMNPNTLMSHGVPVVRTNQCAGEFVITFPRAYHSGFNQGY NFAEAVNFCTADWLPAGRQCIEHYRRLRRYCVFSHEELICKMAAFPETLDLNLAVAVHKEMFIMVQEERR LRKALLEKGVTEAEREAFELLPDDERQCIKCKTTCFLSALACYDCPDGLVCLSHINDLCKCSSSRQYLRY RYTLDELPTMLHKLKIRAESFDTWANKVRVALEVEDGRKRSFEELRALESEARERRFPNSELLQRLKNCL SEVEACIAQVLGLVSGQVARMDTPQLTLTELRVLLEQMGSLPCAMHQIGDVKDVLEQVEAYQAEAREALA TLPSSPGLLRSLLERGQQLGVEVPEAHQLQQQVEQAQWLDEVKQALAPSAHRGSLVIMQGLLVMGAKIAS SPSVDKARAELQELLTIAERWEEKAHFCLEARQKHPPATLEAIIRETENIPVHLPNIQALKEALTKAQAW IADVDEIQNGDHYPCLDDLEGLVAVGRDLPVGLEELRQLELQVLTAHSWREKASKTFLKKNSCYTLLEVL CPCADAGSDSTKRSRWMEKALGLYQCDTELLGLSAQDLRDPGSVIVAFKEGEQKEKEGILQLRRTNSAKP SPLAPSLMASSPTSICVCGQVPAGVGVLQCDLCQDWFHGQCVSVPHLLTSPKPSLTSSPLLAWWEWDTKF LCPLCMRSRRPRLETILALLVALQRLPVRLPEGEALQCLTERAIGWQDRARKALASEDVTALLRQLAELR QQLQAKPRPEEASVYTSATACDPIREGSGNNISKVQGLLENGDSVTSPENMAPGKGSDLELLSSLLPQLT GPVLELPEAIRAPLEELMMEGDLLEVTLDENHSIWQLLQAGQPPDLDRIRTLLELEKFEHQGSRTRSRAL ERRRRRQKVDQGRNVENLVQQELQSKRARSSGIMSQVGREEEHYQEKADRENMFLTPSTDHSPFLKGNQN SLQHKDSGSSAACPSLMPLLQLSYSDEQQL TRTRPLEQKLISEEDLAANDILDYKDDDDKV Restriction Sites: SgfI-MluI Cloning Scheme: This product is to be used for laboratory only. Not for diagnostic or therapeutic use. ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 3 / 5 KDM5D (NM_001146705) Human Tagged ORF Clone – RC229081 Plasmid Map: ACCN: NM_001146705 ORF Size: 4710 bp OTI Disclaimer: The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. More info OTI Annotation: This clone was engineered to express the complete ORF with an expression tag. Expression varies depending on the nature of the gene. RefSeq: NM_001146705.1, NP_001140177.1 RefSeq ORF: 4713 bp Locus ID: 8284 UniProt ID: Q9BY66 Protein Families: Druggable Genome, Transcription Factors MW: 177.4 kDa This product is to be used for laboratory only. Not for diagnostic or therapeutic use. ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 4 / 5 KDM5D (NM_001146705) Human Tagged ORF Clone – RC229081 Gene Summary: This gene encodes a protein containing zinc finger domains. A short peptide derived from this protein is a minor histocompatibility antigen which can lead to graft rejection of male donor cells in a female recipient. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Apr 2009] Product images: Western blot validation of overexpression lysate (Cat# [LY432108]) using anti-DDK antibody (Cat# [TA50011-100]). Left: Cell lysates from un- transfected HEK293T cells; Right: Cell lysates from HEK293T cells transfected with RC229081 using transfection reagent MegaTran 2.0 (Cat# [TT210002]). This product is to be used for laboratory only. Not for diagnostic or therapeutic use. ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 5 / 5.
Load more

Recommended publications
  • Small Molecule Inhibitors of KDM5 Histone Demethylases Increase the Radiosensitivity of Breast Cancer Cells Overexpressing JARID1B
    molecules Article Small Molecule Inhibitors of KDM5 Histone Demethylases Increase the Radiosensitivity of Breast Cancer Cells Overexpressing JARID1B Simone Pippa 1, Cecilia Mannironi 2, Valerio Licursi 1,3, Luca Bombardi 1, Gianni Colotti 2, Enrico Cundari 2, Adriano Mollica 4, Antonio Coluccia 5 , Valentina Naccarato 5, Giuseppe La Regina 5 , Romano Silvestri 5 and Rodolfo Negri 1,2,* 1 Department of Biology and Biotechnology “C. Darwin”, Sapienza University of Rome, 00185 Rome, Italy; [email protected] (S.P.); [email protected] (V.L.); [email protected] (L.B.) 2 Institute of Molecular Biology and Pathology, Italian National Research Council, 00185 Rome, Italy; [email protected] (C.M.); [email protected] (G.C.); [email protected] (E.C.) 3 Institute for Systems Analysis and Computer Science “A. Ruberti”, Italian National Research Council, 00185 Rome, Italy 4 Department of Pharmacy, University “G. d’ Annunzio” of Chieti, Via dei Vestini 31, 66100 Chieti, Italy; [email protected] 5 Department of Drug Chemistry and Technologies, Sapienza University of Rome, Laboratory affiliated to Istituto Pasteur Italia Cenci Bolognetti Foundation, Sapienza University of Rome, 00185 Rome, Italy; [email protected] (A.C.); [email protected] (V.N.); [email protected] (G.L.R.); [email protected] (R.S.) * Correspondence: [email protected]; Tel.: +39-06-4991-7790 Academic Editors: Sergio Valente and Diego Muñoz-Torrero Received: 12 October 2018; Accepted: 1 May 2019; Published: 4 May 2019 Abstract: Background: KDM5 enzymes are H3K4 specific histone demethylases involved in transcriptional regulation and DNA repair. These proteins are overexpressed in different kinds of cancer, including breast, prostate and bladder carcinomas, with positive effects on cancer proliferation and chemoresistance.
    [Show full text]
  • Modes of Interaction of KMT2 Histone H3 Lysine 4 Methyltransferase/COMPASS Complexes with Chromatin
    cells Review Modes of Interaction of KMT2 Histone H3 Lysine 4 Methyltransferase/COMPASS Complexes with Chromatin Agnieszka Bochy ´nska,Juliane Lüscher-Firzlaff and Bernhard Lüscher * ID Institute of Biochemistry and Molecular Biology, Medical School, RWTH Aachen University, Pauwelsstrasse 30, 52057 Aachen, Germany; [email protected] (A.B.); jluescher-fi[email protected] (J.L.-F.) * Correspondence: [email protected]; Tel.: +49-241-8088850; Fax: +49-241-8082427 Received: 18 January 2018; Accepted: 27 February 2018; Published: 2 March 2018 Abstract: Regulation of gene expression is achieved by sequence-specific transcriptional regulators, which convey the information that is contained in the sequence of DNA into RNA polymerase activity. This is achieved by the recruitment of transcriptional co-factors. One of the consequences of co-factor recruitment is the control of specific properties of nucleosomes, the basic units of chromatin, and their protein components, the core histones. The main principles are to regulate the position and the characteristics of nucleosomes. The latter includes modulating the composition of core histones and their variants that are integrated into nucleosomes, and the post-translational modification of these histones referred to as histone marks. One of these marks is the methylation of lysine 4 of the core histone H3 (H3K4). While mono-methylation of H3K4 (H3K4me1) is located preferentially at active enhancers, tri-methylation (H3K4me3) is a mark found at open and potentially active promoters. Thus, H3K4 methylation is typically associated with gene transcription. The class 2 lysine methyltransferases (KMTs) are the main enzymes that methylate H3K4. KMT2 enzymes function in complexes that contain a necessary core complex composed of WDR5, RBBP5, ASH2L, and DPY30, the so-called WRAD complex.
    [Show full text]
  • Imidazopyridines As Potent KDM5 Demethylase Inhibitors Promoting Reprogramming Efficiency of Human Ipscs
    Article Imidazopyridines as Potent KDM5 Demethylase Inhibitors Promoting Reprogramming Efficiency of Human iPSCs Yasamin Dabiri, Rodrigo A. Gama- Brambila, Katerina Taskova, ..., Jichang Wang, Miguel A. Andrade-Navarro, Xinlai Cheng [email protected] HIGHLIGHTS O4I3 supports the maintenance and generation of human iPSCs O4I3 is a potent H3K4 demethylase KDM5 inhibitor in vitro and in cells KDM5A, but not KDM5B, serves as an epigenetic barrier of reprogramming Chemical or genetic inhibition of KDM5A tends to promote the reprogramming efficiency Dabiri et al., iScience 12,168– 181 February 22, 2019 ª 2019 The Author(s). https://doi.org/10.1016/ j.isci.2019.01.012 Article Imidazopyridines as Potent KDM5 Demethylase Inhibitors Promoting Reprogramming Efficiency of Human iPSCs Yasamin Dabiri,1 Rodrigo A. Gama-Brambila,1 Katerina Taskova,2,3 Kristina Herold,4 Stefanie Reuter,4 James Adjaye,5 Jochen Utikal,6 Ralf Mrowka,4 Jichang Wang,7 Miguel A. Andrade-Navarro,2,3 and Xinlai Cheng1,8,* SUMMARY Pioneering human induced pluripotent stem cell (iPSC)-based pre-clinical studies have raised safety concerns and pinpointed the need for safer and more efficient approaches to generate and maintain patient-specific iPSCs. One approach is searching for compounds that influence pluripotent stem cell reprogramming using functional screens of known drugs. Our high-throughput screening of drug-like hits showed that imidazopyridines—analogs of zolpidem, a sedative-hypnotic drug—are able to improve reprogramming efficiency and facilitate reprogramming of resistant human primary fibro- blasts. The lead compound (O4I3) showed a remarkable OCT4 induction, which at least in part is 1Institute of Pharmacy and due to the inhibition of H3K4 demethylase (KDM5, also known as JARID1).
    [Show full text]
  • Prox1regulates the Subtype-Specific Development of Caudal Ganglionic
    The Journal of Neuroscience, September 16, 2015 • 35(37):12869–12889 • 12869 Development/Plasticity/Repair Prox1 Regulates the Subtype-Specific Development of Caudal Ganglionic Eminence-Derived GABAergic Cortical Interneurons X Goichi Miyoshi,1 Allison Young,1 Timothy Petros,1 Theofanis Karayannis,1 Melissa McKenzie Chang,1 Alfonso Lavado,2 Tomohiko Iwano,3 Miho Nakajima,4 Hiroki Taniguchi,5 Z. Josh Huang,5 XNathaniel Heintz,4 Guillermo Oliver,2 Fumio Matsuzaki,3 Robert P. Machold,1 and Gord Fishell1 1Department of Neuroscience and Physiology, NYU Neuroscience Institute, Smilow Research Center, New York University School of Medicine, New York, New York 10016, 2Department of Genetics & Tumor Cell Biology, St. Jude Children’s Research Hospital, Memphis, Tennessee 38105, 3Laboratory for Cell Asymmetry, RIKEN Center for Developmental Biology, Kobe 650-0047, Japan, 4Laboratory of Molecular Biology, Howard Hughes Medical Institute, GENSAT Project, The Rockefeller University, New York, New York 10065, and 5Cold Spring Harbor Laboratory, Cold Spring Harbor, New York 11724 Neurogliaform (RELNϩ) and bipolar (VIPϩ) GABAergic interneurons of the mammalian cerebral cortex provide critical inhibition locally within the superficial layers. While these subtypes are known to originate from the embryonic caudal ganglionic eminence (CGE), the specific genetic programs that direct their positioning, maturation, and integration into the cortical network have not been eluci- dated. Here, we report that in mice expression of the transcription factor Prox1 is selectively maintained in postmitotic CGE-derived cortical interneuron precursors and that loss of Prox1 impairs the integration of these cells into superficial layers. Moreover, Prox1 differentially regulates the postnatal maturation of each specific subtype originating from the CGE (RELN, Calb2/VIP, and VIP).
    [Show full text]
  • X Chromosome Dosage of Histone Demethylase KDM5C Determines Sex Differences in Adiposity
    X chromosome dosage of histone demethylase KDM5C determines sex differences in adiposity Jenny C. Link, … , Arthur P. Arnold, Karen Reue J Clin Invest. 2020. https://doi.org/10.1172/JCI140223. Research Article Genetics Metabolism Graphical abstract Find the latest version: https://jci.me/140223/pdf The Journal of Clinical Investigation RESEARCH ARTICLE X chromosome dosage of histone demethylase KDM5C determines sex differences in adiposity Jenny C. Link,1 Carrie B. Wiese,2 Xuqi Chen,3 Rozeta Avetisyan,2 Emilio Ronquillo,2 Feiyang Ma,4 Xiuqing Guo,5 Jie Yao,5 Matthew Allison,6 Yii-Der Ida Chen,5 Jerome I. Rotter,5 Julia S. El -Sayed Moustafa,7 Kerrin S. Small,7 Shigeki Iwase,8 Matteo Pellegrini,4 Laurent Vergnes,2 Arthur P. Arnold,3 and Karen Reue1,2 1Molecular Biology Institute, 2Human Genetics, David Geffen School of Medicine, 3Integrative Biology and Physiology, and 4Molecular, Cellular and Developmental Biology, UCLA, Los Angeles, California, USA. 5Institute for Translational Genomics and Population Sciences, Department of Pediatrics, Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California, USA. 6Division of Preventive Medicine, School of Medicine, UCSD, San Diego, California, USA. 7Department of Twin Research and Genetic Epidemiology, King’s College London, London, United Kingdom. 8Human Genetics, Medical School, University of Michigan, Ann Arbor, Michigan, USA. Males and females differ in body composition and fat distribution. Using a mouse model that segregates gonadal sex (ovaries and testes) from chromosomal sex (XX and XY), we showed that XX chromosome complement in combination with a high-fat diet led to enhanced weight gain in the presence of male or female gonads.
    [Show full text]
  • 1714 Gene Comprehensive Cancer Panel Enriched for Clinically Actionable Genes with Additional Biologically Relevant Genes 400-500X Average Coverage on Tumor
    xO GENE PANEL 1714 gene comprehensive cancer panel enriched for clinically actionable genes with additional biologically relevant genes 400-500x average coverage on tumor Genes A-C Genes D-F Genes G-I Genes J-L AATK ATAD2B BTG1 CDH7 CREM DACH1 EPHA1 FES G6PC3 HGF IL18RAP JADE1 LMO1 ABCA1 ATF1 BTG2 CDK1 CRHR1 DACH2 EPHA2 FEV G6PD HIF1A IL1R1 JAK1 LMO2 ABCB1 ATM BTG3 CDK10 CRK DAXX EPHA3 FGF1 GAB1 HIF1AN IL1R2 JAK2 LMO7 ABCB11 ATR BTK CDK11A CRKL DBH EPHA4 FGF10 GAB2 HIST1H1E IL1RAP JAK3 LMTK2 ABCB4 ATRX BTRC CDK11B CRLF2 DCC EPHA5 FGF11 GABPA HIST1H3B IL20RA JARID2 LMTK3 ABCC1 AURKA BUB1 CDK12 CRTC1 DCUN1D1 EPHA6 FGF12 GALNT12 HIST1H4E IL20RB JAZF1 LPHN2 ABCC2 AURKB BUB1B CDK13 CRTC2 DCUN1D2 EPHA7 FGF13 GATA1 HLA-A IL21R JMJD1C LPHN3 ABCG1 AURKC BUB3 CDK14 CRTC3 DDB2 EPHA8 FGF14 GATA2 HLA-B IL22RA1 JMJD4 LPP ABCG2 AXIN1 C11orf30 CDK15 CSF1 DDIT3 EPHB1 FGF16 GATA3 HLF IL22RA2 JMJD6 LRP1B ABI1 AXIN2 CACNA1C CDK16 CSF1R DDR1 EPHB2 FGF17 GATA5 HLTF IL23R JMJD7 LRP5 ABL1 AXL CACNA1S CDK17 CSF2RA DDR2 EPHB3 FGF18 GATA6 HMGA1 IL2RA JMJD8 LRP6 ABL2 B2M CACNB2 CDK18 CSF2RB DDX3X EPHB4 FGF19 GDNF HMGA2 IL2RB JUN LRRK2 ACE BABAM1 CADM2 CDK19 CSF3R DDX5 EPHB6 FGF2 GFI1 HMGCR IL2RG JUNB LSM1 ACSL6 BACH1 CALR CDK2 CSK DDX6 EPOR FGF20 GFI1B HNF1A IL3 JUND LTK ACTA2 BACH2 CAMTA1 CDK20 CSNK1D DEK ERBB2 FGF21 GFRA4 HNF1B IL3RA JUP LYL1 ACTC1 BAG4 CAPRIN2 CDK3 CSNK1E DHFR ERBB3 FGF22 GGCX HNRNPA3 IL4R KAT2A LYN ACVR1 BAI3 CARD10 CDK4 CTCF DHH ERBB4 FGF23 GHR HOXA10 IL5RA KAT2B LZTR1 ACVR1B BAP1 CARD11 CDK5 CTCFL DIAPH1 ERCC1 FGF3 GID4 HOXA11 IL6R KAT5 ACVR2A
    [Show full text]
  • Histone Demethylases at the Center of Cellular Differentiation and Disease
    Downloaded from genesdev.cshlp.org on September 30, 2021 - Published by Cold Spring Harbor Laboratory Press REVIEW Erasing the methyl mark: histone demethylases at the center of cellular differentiation and disease Paul A.C. Cloos,2 Jesper Christensen, Karl Agger, and Kristian Helin1 Biotech Research and Innovation Centre (BRIC) and Centre for Epigenetics, University of Copenhagen, DK-2200 Copenhagen, Denmark The enzymes catalyzing lysine and arginine methylation impacts on the transcriptional activity of the underlying of histones are essential for maintaining transcriptional DNA by acting as a recognition template for effector programs and determining cell fate and identity. Until proteins modifying the chromatin environment and lead- recently, histone methylation was regarded irreversible. ing to either repression or activation. Thus, histone However, within the last few years, several families of methylation can be associated with either activation or histone demethylases erasing methyl marks associated repression of transcription depending on which effector with gene repression or activation have been identified, protein is being recruited. It should be noted that the underscoring the plasticity and dynamic nature of his- unmodified residues can also serve as a binding template tone methylation. Recent discoveries have revealed that for effector proteins leading to specific chromatin states histone demethylases take part in large multiprotein (Lan et al. 2007b). complexes synergizing with histone deacetylases, histone Arginine residues can be modified by one or two meth- methyltransferases, and nuclear receptors to control de- yl groups; the latter form in either a symmetric or asym- velopmental and transcriptional programs. Here we re- metric conformation (Rme1, Rme2s, and Rme2a), per- view the emerging biochemical and biological functions mitting a total of four states: one unmethylated and of the histone demethylases and discuss their potential three methylated forms.
    [Show full text]
  • (P -Value<0.05, Fold Change≥1.4), 4 Vs. 0 Gy Irradiation
    Table S1: Significant differentially expressed genes (P -Value<0.05, Fold Change≥1.4), 4 vs. 0 Gy irradiation Genbank Fold Change P -Value Gene Symbol Description Accession Q9F8M7_CARHY (Q9F8M7) DTDP-glucose 4,6-dehydratase (Fragment), partial (9%) 6.70 0.017399678 THC2699065 [THC2719287] 5.53 0.003379195 BC013657 BC013657 Homo sapiens cDNA clone IMAGE:4152983, partial cds. [BC013657] 5.10 0.024641735 THC2750781 Ciliary dynein heavy chain 5 (Axonemal beta dynein heavy chain 5) (HL1). 4.07 0.04353262 DNAH5 [Source:Uniprot/SWISSPROT;Acc:Q8TE73] [ENST00000382416] 3.81 0.002855909 NM_145263 SPATA18 Homo sapiens spermatogenesis associated 18 homolog (rat) (SPATA18), mRNA [NM_145263] AA418814 zw01a02.s1 Soares_NhHMPu_S1 Homo sapiens cDNA clone IMAGE:767978 3', 3.69 0.03203913 AA418814 AA418814 mRNA sequence [AA418814] AL356953 leucine-rich repeat-containing G protein-coupled receptor 6 {Homo sapiens} (exp=0; 3.63 0.0277936 THC2705989 wgp=1; cg=0), partial (4%) [THC2752981] AA484677 ne64a07.s1 NCI_CGAP_Alv1 Homo sapiens cDNA clone IMAGE:909012, mRNA 3.63 0.027098073 AA484677 AA484677 sequence [AA484677] oe06h09.s1 NCI_CGAP_Ov2 Homo sapiens cDNA clone IMAGE:1385153, mRNA sequence 3.48 0.04468495 AA837799 AA837799 [AA837799] Homo sapiens hypothetical protein LOC340109, mRNA (cDNA clone IMAGE:5578073), partial 3.27 0.031178378 BC039509 LOC643401 cds. [BC039509] Homo sapiens Fas (TNF receptor superfamily, member 6) (FAS), transcript variant 1, mRNA 3.24 0.022156298 NM_000043 FAS [NM_000043] 3.20 0.021043295 A_32_P125056 BF803942 CM2-CI0135-021100-477-g08 CI0135 Homo sapiens cDNA, mRNA sequence 3.04 0.043389246 BF803942 BF803942 [BF803942] 3.03 0.002430239 NM_015920 RPS27L Homo sapiens ribosomal protein S27-like (RPS27L), mRNA [NM_015920] Homo sapiens tumor necrosis factor receptor superfamily, member 10c, decoy without an 2.98 0.021202829 NM_003841 TNFRSF10C intracellular domain (TNFRSF10C), mRNA [NM_003841] 2.97 0.03243901 AB002384 C6orf32 Homo sapiens mRNA for KIAA0386 gene, partial cds.
    [Show full text]
  • KDM5A and KDM5B Histone-Demethylases Contribute To
    © 2021. Published by The Company of Biologists Ltd | Biology Open (2021) 10, bio057729. doi:10.1242/bio.057729 RESEARCH ARTICLE KDM5A and KDM5B histone-demethylases contribute to HU-induced replication stress response and tolerance Solenne Gaillard1, Virginie Charasson1, Cyril Ribeyre2, Kader Salifou2, Marie-Jeanne Pillaire3, Jean-Sebastien Hoffmann4, Angelos Constantinou2, Didier Trouche1,* and Marie Vandromme1,* ABSTRACT van Oevelen et al., 2008; Pasini et al., 2008; Tahiliani et al., KDM5A and KDM5B histone-demethylases are overexpressed in 2007). However, they can also function in some instances as many cancers and have been involved in drug tolerance. Here, we co-activators. This positive effect on transcription may involve or describe that KDM5A, together with KDM5B, contribute to replication not their enzymatic activity and can result from the ability of stress (RS) response and tolerance. First, they positively regulate KDM5A or KDM5B to prevent spreading of H3K4 methylation RRM2, the regulatory subunit of ribonucleotide reductase. Second, into gene bodies (Hayakawa et al., 2007; Xie et al., 2011), or from they are required for optimal levels of activated Chk1, a major player of binding of KDM5B or KDM5C at enhancer regions to maintain the intra-S phase checkpoint that protects cells from RS. We also H3K4 mono-methylation levels (Kidder et al., 2014; Outchkourov found that KDM5A is enriched at ongoing replication forks and et al., 2013; Shen et al., 2016). Rather surprisingly, KDM5A and associates with both PCNA and Chk1. Because RRM2 is a major KDM5B bind to promoters of actively transcribed genes enriched determinant of replication stress tolerance, we developed cells in H3K4me3 (Beshiri et al., 2010; Liu and Secombe, 2015; resistant to HU, and show that KDM5A/B proteins are required for Lopez-Bigas et al., 2008), meaning that their demethylase activity is both RRM2 overexpression and tolerance to HU.
    [Show full text]
  • Regulation of ZMYND8 to Treat Cancer
    molecules Review Regulation of ZMYND8 to Treat Cancer Yun Chen 1,2 , Ya-Hui Tsai 1,2,* and Sheng-Hong Tseng 1,3,* 1 Department of Surgery, Far Eastern Memorial Hospital, Pan-Chiao, New Taipei 220, Taiwan; [email protected] 2 Department of Chemical Engineering and Materials Science, Yuan Ze University, Chung-Li, Taoyuan 320, Taiwan 3 Department of Surgery, National Taiwan University Hospital, Taipei 100, Taiwan * Correspondence: [email protected] (Y.-H.T.); [email protected] (S.-H.T.); Tel.: +886-2-89-667-000 (ext. 2923) (Y.-H.T.); +886-2-23-123-456 (ext. 65110) (S.-H.T.) Abstract: Zinc finger myeloid, nervy, and deformed epidermal autoregulatory factor 1-type con- taining 8 (Zinc finger MYND-type containing 8, ZMYND8) is a transcription factor, a histone H3- interacting protein, and a putative chromatin reader/effector that plays an essential role in regulating transcription during normal cellular growth. Mutations and altered expression of ZMYND8 are associated with the development and progression of cancer. Increased expression of ZMYND8 is linked to breast, prostate, colorectal, and cervical cancers. It exerts pro-oncogenic effects in breast and prostate cancers, and it promotes angiogenesis in zebrafish, as well as in breast and prostate cancers. In contrast, downregulation of ZMYND8 is also reported in breast, prostate, and nasopharyngeal cancers. ZMYND8 acts as a tumor suppressor in breast and prostate cancers, and it inhibits tumor growth by promoting differentiation; inhibiting proliferation, cell-cycle progression, invasiveness, and metastasis; and maintaining the epithelial phenotype in various types of cancers. These data together suggest that ZMYND8 is important in tumorigenesis; however, the existing data are con- tradictory.
    [Show full text]
  • X- and Y-Linked Chromatin-Modifying Genes As Regulators of Sex-Specific Cancer Incidence and Prognosis
    Author Manuscript Published OnlineFirst on July 30, 2020; DOI: 10.1158/1078-0432.CCR-20-1741 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. X- and Y-linked chromatin-modifying genes as regulators of sex- specific cancer incidence and prognosis Rossella Tricarico1,2,*, Emmanuelle Nicolas1, Michael J. Hall 3, and Erica A. Golemis1,* 1Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA, 19111, USA; 2Department of Biology and Biotechnology, University of Pavia, 27100 Pavia, Italy; 3Cancer Prevention and Control Program, Department of Clinical Genetics, Fox Chase Cancer Center, Philadelphia, PA, 19111, USA Running title: Allosomally linked epigenetic regulators in cancer Conflict Statement: The authors declare no conflict of interest. Funding: The authors are supported by NIH DK108195 and CA228187 (to EAG), by NCI Core Grant CA006927 (to Fox Chase Cancer Center), and by a Marie Curie Individual Fellowship from the Horizon 2020 EU Program (to RT). * Correspondence should be directed to: Erica A. Golemis Fox Chase Cancer Center 333 Cottman Ave. Philadelphia, PA 19111 USA [email protected] (215) 728-2860 or Rossella Tricarico Department of Biology and Biotechnology University of Pavia Via Ferrata 9, 27100 Pavia, Italy [email protected] +39 340-2429631 1 Downloaded from clincancerres.aacrjournals.org on September 25, 2021. © 2020 American Association for Cancer Research. Author Manuscript Published OnlineFirst on July 30, 2020; DOI: 10.1158/1078-0432.CCR-20-1741 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Abstract Biological sex profoundly conditions organismal development and physiology, imposing wide-ranging effects on cell signaling, metabolism, and immune response.
    [Show full text]
  • The Emerging Role of KDM5A in Human Cancer
    Yang et al. J Hematol Oncol (2021) 14:30 https://doi.org/10.1186/s13045-021-01041-1 REVIEW Open Access The emerging role of KDM5A in human cancer Guan‑Jun Yang1,2,3,4 , Ming‑Hui Zhu1,2,3, Xin‑Jiang Lu1,2,3, Yan‑Jun Liu5, Jian‑Fei Lu1,2,3, Chung‑Hang Leung4*, Dik‑Lung Ma6* and Jiong Chen1,2,3* Abstract Histone methylation is a key posttranslational modifcation of chromatin, and its dysregulation afects a wide array of nuclear activities including the maintenance of genome integrity, transcriptional regulation, and epigenetic inherit‑ ance. Variations in the pattern of histone methylation infuence both physiological and pathological events. Lysine‑ specifc demethylase 5A (KDM5A, also known as JARID1A or RBP2) is a KDM5 Jumonji histone demethylase subfamily member that erases di‑ and tri‑methyl groups from lysine 4 of histone H3. Emerging studies indicate that KDM5A is responsible for driving multiple human diseases, particularly cancers. In this review, we summarize the roles of KDM5A in human cancers, survey the feld of KDM5A inhibitors including their anticancer activity and modes of action, and the current challenges and potential opportunities of this feld. Keywords: KDM5A, Cancer, Jumonji C domain, Histone methylation, Drug resistance, Targeted therapy Background NUP98 and KDM5A, mediates hematopoietic cell prolif- Lysine-specifc demethylase 5A (KDM5A), also named eration and alters myelo-erythropoietic diferentiation via Jumonji/ARID domain-containing protein 1A (JARID1A) demethylating H3K4me2/3 [14–17]. In terms of mecha- or retinoblastoma-binding protein 2 (RBP2), origi- nism, KDM5A and its fusion gene Fe(II)-dependently nally reported as a retinoblastoma protein (RB) pocket catalyzes oxidative decarboxylation of 2OG with con- domain-binding protein in 2001 [1], is a Fe(II)- and sumption of O2 to generate a reactive iron(IV)-oxo inter- α-ketoglutaric acid (2OG)-dependent JmjC-containing mediate, carbon dioxide, and succinate.
    [Show full text]